Press Releases AstraZeneca PLC

Stocks

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:07 2026-07-22 am EDT			5-day change	1st Jan Change
12,702.00 ^GBX	+1.68%		+1.08%	-7.89%

08:52am	What Bundibugyo Ebola vaccines and treatments are under development	RE
07:40am	Royalty Pharma Acquires Royalty Interest in AstraZeneca's Cliramitug	MT

Press Releases

Jul. 15	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy	AQ
Jul. 14	AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical	PU
Jun. 29	AstraZeneca : Enhertu approved in EU for HER2+ solid tumours	PU
Jun. 29	AstraZeneca : Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours	PU
Jun. 29	AstraZeneca : Datroway recommended for approval in EU for TNBC	PU
Jun. 28	AstraZeneca : Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial	PU
Jun. 26	AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy	PU
Jun. 24	AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care	BU
Jun. 15	AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy	PU
Jun. 15	AstraZeneca : Truqap approved in US for prostate cancer	PU
Jun. 12	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
Jun. 12	AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
Jun. 08	AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio	PU
Jun. 07	CEO of AstraZeneca: “AI is fundamentally changing the way we develop medicines”	AQ
Jun. 02	Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026	AQ
Jun. 02	AstraZeneca - Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	AQ
Jun. 02	Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial	BU
Jun. 01	AstraZeneca : Presentation (ASCO2026 Presentation 20260601)	PU
Jun. 01	AstraZeneca : Biographies (ASCO2026 biographies 20260601)	PU
Jun. 01	IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial	BU
May. 29	AstraZeneca : CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis	PU
May. 28	IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer	BU
May. 28	AstraZeneca : Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.	PU
May. 22	DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	BU
May. 22	AstraZeneca : Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	PU